Durable remission after splenectomy for Waldenström's macroglobulinemia with massive splenomegaly in leukemic phase.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Leukemia and Lymphoma

• Publication date

  1997-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428199709051789PMID 9322902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Durable complete remission of macroglobulinemia after splenectomy: A report of two cases and review of the literature

  1995cited by this paper
• Splenectomy followed by local injections of interferon‐α is effective for treating cutaneous‐type adult T‐cell leukaemia/lymphoma

  1993cited by this paper
• Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance

  1989cited by this paper
• The clinical and cellular aspects of Waldenström's macroglobulinaemia.

  1988cited by this paper
• Lymphocyte and complement abnormalities in splenectomized patients with hematologic disorders

  1988cited by this paper
• Immunosuppressive factor from the spleen in gastric cancer patients

  1985cited by this paper
• Alterations in immunoglobulin synthesis by peripheral blood mononuclear cells from splenectomized patients with and without splenic regrowth.

  1984cited by this paper
• Peripheral blood mononuclear cells of splenectomized patients are unable to differentiate into immunoglobulin-secreting cells after pokeweed mitogen stimulation.

  1984cited by this paper
• Lymphocyte subsets in normal human lymphoid tissues.

  1983cited by this paper
• Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine.

  1981cited by this paper
• The role of the spleen in tumor growth kinetics of the murine B cell leukemia (BCL1).

  1980cited by this paper
• The pathology and homing of a transplantable murine B cell leukemia (BCL1).

  1979cited by this paper
• Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody.

  1979cited by this paper
• Soluble suppressor factor from the spleens of tumor-bearing mice.

  1978cited by this paper
• Effects of splenectomy on the humoral immune system. A study in neonatally and adult splenectomized mice.

  1978cited by this paper
• Effect of splenectomy in tumor-bearing mice and gastric cancer patients.

  1977cited by this paper
• [Postoperative changes in immunoglobulin-concentrations after splenectomy. A prospective survey series (author's transl)].

  1976cited by this paper
• Suppressor factor secreted by T-lymphocytes from tumor-bearing mice.

  1976cited by this paper
• Immune competence of hereditarily asplenic mice.

  1974cited by this paper
• Elution of “blocking factors” from human tumors, capable of abrogating tumor‐cell destruction by specifically immune lymphocytes

  1972cited by this paper
• Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms

  1971cited by this paper
• Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas.

  1970cited by this paper

• Clinicopathological profile of Waldenström's macroglobulinemia: Experience from a tertiary care center

  2020cites this paper
• Radiation Therapy in Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

  2018cites this paper
• Anemia hemolítica como manifestación inicial de macroglobulinemia de Waldenström

  2018cites this paper
• Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular α-Particle Therapy of Cancer

  2014cites this paper
• The Role of Radiation Therapy in the Treatment of Multiple Myeloma, Plasmacytoma, and Other Plasma Cell Disorders

  2014cites this paper
• disease Waldenström macroglobulinemia in first relapse or with primary refractory of cyclophosphamide-doxorubicin-prednisone in 92 patients with Multicenter, randomized comparative trial of fludarabine and the combination

  2013cites this paper
• Splenic re-irradiation for waldenstrőm’s macroglobulinemia

  2012cites this paper
• Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer

  2010cites this paper
• Splenectomy in plasma cell dyscrasias: A review of the clinical practice

  2006cites this paper
• Macroglobulinemia de Waldenström

  2006cites this paper
• Treatment for Waldenstrom's macroglobulinemia.

  2004cites this paper
• Waldenstrom’s Macroglobulinemia treated with fractionated low-dose total body irradiation

  2004cites this paper
• Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

  2003cites this paper
• Waldenström's Macroglobulinemia: A Review of Therapy

  2002cites this paper
• Advanced Waldenström’s Macroglobulinemia: A Case of Possible Cure after Systemic Chemotherapy, Splenic Radiation and Splenectomy

  2002cites this paper
• Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.

  2001cites this paper
• Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma

  2001cites this paper
• Waldenström's macroglobulinemia.

  2000cites this paper
• Waldenström's macroglobulinemia: clinical features, complications, and management.

  2000cites this paper